When does bevacizumab’s patent protection end?
Bevacizumab’s key patents are tied to specific geographic markets and to the different kinds of exclusivity involved (the original patents, plus any extensions or later “second‑generation” formulations or process patents). Because of that, the exact date “it comes off patent” varies by country.
DrugPatentWatch tracks these timeframes by jurisdiction and patent family, and is the most direct way to check the specific “off-patent” date for the market you care about. You can look it up here: https://www.drugpatentwatch.com/p/bevacizumab
How to find the exact “off-patent” date for your country
Search DrugPatentWatch for bevacizumab and filter to the country/region of interest. The site reports the relevant patent expiries (by patent family) so you can see:
- which patents are driving the remaining exclusivity window, and
- what date each one expires in that jurisdiction.
That’s the practical answer to “when does it come off patent” for real-world generic/biosimilar entry timing.
Does “off patent” mean generics or biosimilars can launch immediately?
Not always. Even after primary patents expire, entry can still be delayed by:
- other still-active patents in the same or related families,
- regulatory exclusivity periods (where applicable), and
- patent litigation or settlements that affect launch timing.
So “off patent” is a necessary but sometimes not sufficient condition for market entry.
What if you mean the originator product versus the molecule?
Sometimes the bottle date people cite (e.g., product-specific exclusivity or particular formulation/process patents) differs from the molecule’s broad patent landscape. Checking the specific bevacizumab product/patent family in your target market on DrugPatentWatch avoids mixing up those timelines.
Sources
- https://www.drugpatentwatch.com/p/bevacizumab